NCT07093554 is a Phase 1 clinical trial of Talquetamab in Relapse Multiple Myeloma, sponsored by Medical College of Wisconsin.

Who is sponsoring NCT07093554?

NCT07093554 is sponsored by Medical College of Wisconsin.

What drugs are being tested in NCT07093554?

Interventions in NCT07093554: Talquetamab, Ciltacabtagene Autoleucel.

What condition does NCT07093554 study?

NCT07093554 studies Relapse Multiple Myeloma, Refractory Multiple Myeloma.

Is NCT07093554 still recruiting?

NCT07093554 is currently recruiting now. Last updated 5 January 2026.

Last reviewed 2026-01-05 · How we verify

NCT07093554

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting now Phase 1 Last updated 5 January 2026

What this trial tests

Phase 1 trial testing Talquetamab in Relapse Multiple Myeloma in 31 participants. Currently enrolling.

Timeline

2 December 2025

Primary endpoint
1 July 2027

1 January 2028

Quick facts

Lead sponsor	Medical College of Wisconsin
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	31
Start date	2 December 2025
Primary completion	1 July 2027
Estimated completion	1 January 2028
Sites	1 location across United States

Drugs / interventions tested

Talquetamab (TALQUETAMAB) — full drug profile →
Ciltacabtagene Autoleucel (ciltacabtagene autoleucel) — full drug profile →

Conditions studied

Relapse Multiple Myeloma — all drugs for Relapse Multiple Myeloma →
Refractory Multiple Myeloma — all drugs for Refractory Multiple Myeloma →

Sponsor

Medical College of Wisconsin

Who can join

18 and older, any sex, with Relapse Multiple Myeloma or Refractory Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-arm, open-label, phase 1b study evaluating the safety and feasibility of using talquetamab as bridging therapy prior to cilta-cel in patients with relapsed and refractory multiple myeloma (RRMM).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Talquetamab

Trials testing the same drug.

NCT07499323 — Talquetamab in Patients With Refractory Generalized Myasthenia Gravis · NA · not yet recruiting
NCT07032714 — Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma · Phase 1 · recruiting
NCT06572605 — External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extr · Phase 1, PHASE2 · recruiting
NCT06348108 — Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT06550895 — A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma · Phase 2 · active not recruiting

Other recruiting trials for Relapse Multiple Myeloma

Currently open trials in the same condition.

NCT07359014 — Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma · NA · recruiting
NCT06799026 — A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in · Phase 1 · recruiting
NCT06171685 — MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM · Phase 2 · recruiting
NCT06138275 — Elranatamab in R/R Multiple Myeloma · Phase 2 · recruiting
NCT05789303 — Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma · Phase 2 · recruiting

Other Medical College of Wisconsin trials

Trials by the same sponsor.

NCT07260552 — Rapid Engagement for Solutions to Population and Outcomes Through Networked Dialogue for Coronary Heart Disease · not yet recruiting
NCT06795360 — Weight Changes After Incretin-mimetics · NA · not yet recruiting
NCT07228208 — Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes · NA · not yet recruiting
NCT07298460 — Stimulation-based Therapy to Improve Balance in DCM · Phase 1, PHASE2 · not yet recruiting
NCT07434544 — Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07093554 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical College of Wisconsin
Last refreshed: 5 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07093554.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing